Georgy Technology Leadership, Inc. – Trademark Portfolio
Entity Type: 03
Georgy Technology Leadership, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include G-TECHNOLOGY HEALTH. The owner is based in Los Angeles, CA.
Suite 102
8939 South Sepulveda Blvd.
Los Angeles, CA 90045
Showing of trademarks Trademarks
Trademark Classifications
Georgy Technology Leadership, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Georgy Technology Leadership, Inc. have?
Georgy Technology Leadership, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does Georgy Technology Leadership, Inc. file in?
Georgy Technology Leadership, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 35 covers advertising; business management; business administration; office functions.
What are Georgy Technology Leadership, Inc.'s most well-known trademarks?
Georgy Technology Leadership, Inc.'s registered trademark portfolio includes well-known marks such as G-TECHNOLOGY HEALTH. These are among 1 currently registered trademark in the portfolio.
What is Georgy Technology Leadership, Inc.'s trademark registration success rate?
Georgy Technology Leadership, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.